Aldeyra Therapeutics

Aldeyra Therapeutics, Inc. develops drug candidates for capturing and removing free aldehydes to treat and prevent diseases

Aldeyra Therapeutics, Inc. develops drug candidates for capturing and removing free aldehydes to treat and prevent diseases, and slow the progression of chronic disease. The company’s products target immune-mediated, inflammatory, orphan, and other diseases. It develops NS2, a compound that binds and traps free aldehydes. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is based in Burlington, Massachusetts.